Helix Biopharma Corp. · TSX:HBP
Helix Biopharma — Investor Presentation (August 2026)
34 slides from Helix Biopharma's investor presentation, August 2026
Slide 1: Shaping a near future where today's hard-to-treat cancers are vincible
Shaping a near future where today’s hard-to-treat cancers are vincible. As featured in: (US Audiences Only) PUBLIC Company Presentation, Q3 2026
Slide 2: A person facing illness has only one wish
“ I am a stage 4 lung cancer patient and have A HEALTHY PERSON HAS 1000 WISHES. been on L-DOS47 [with chemotherapy] since A PERSON June of 2017. To date my tumor has shrunk by FACING ILLNESS 99%! Early on in my diagnosis I was told I had maybe four months to live. I am now in HAS ONLY ONE. remission
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS Helix BioPharma is on a mission to level the playing field against cancer’s biggest, most urgent challenges. INNOVATING FROM STRENGTH FOCUSED, AMBITIOUS PLAN AHEAD Assets with great potential and a head start Relocation to the US and NASDAQ listing Management team with a track
Slide 4: Our Pipeline
OUR PIPELINE Diverse, clinical-stage pipeline of candidates with great potential and a head start, honed into first- and best-in-class oncology medicines. PRODUCT / TYPE DISCOVERY PRECLINICAL PHASE IA/B PATENT LIFE L-DOS47 2036 Tumor microenvironment Non-Small Cell Lung Cancer (NSCLC) + extensions T
Slide 5: Lead Indications
LEAD INDICATIONS Prevalent and hard-to-treat cancers made vincible by novel therapies that rise to the challenge. HOW WE WANT TO MOVE THE NEEDLE LEAD INDICATIONS, GLOBAL INCIDENCE (MILLIONS) Lung cancer 2.5M ADD ≥30% EFFICACY to immune checkpoint inhibitors (ICIs) standard of care Breast cancer 2.3M
Slide 6: Investment & Return
INVESTMENT & RETURN USD 80M to achieve major project milestones and value inflection points for L-DOS47 and LEUMUNA as priority projects. USE OF PROCEEDS OVER THE NEXT 36 MONTHS THE WHOLE IS GREATER THAN THE SUM OF ITS PARTS CORPORATE CEACAM6 PLATFORM Grow world-class Phase IB + Phase II team random
Slide 7: Who We Are
WHO WE ARE A team built to translate science into value in oncology. LEADERSHIP & CORPORATE AFFAIRS Thomas Mehrling, MD, PhD Veronika Kandziora Rohit Babbar, CPA, CA Jessica Kourniaktis, DPhil Helen Middleton, LPC Chief Executive Officer Chief Operating Officer Chief Financial Officer Director of Co
Slide 8: L-DOS47
L-DOS47 A first-in-class, clinical-stage antibody-enzyme conjugate (AEC) delivering a game-changing assist to anti-tumor immunity and blockbuster cancer immunotherapies. 7
Slide 9: Tumor Acidosis
THE PROBLEM TUMOR ACIDOSIS The success of immune checkpoint inhibitors (ICIs) 70% of cancer patients don’t respond to immunotherapy.1 depends on the availability of functioning immune cells to mobilize against the tumor. But in the acidic microenvironment of solid Immunologically “cold” The acidic t
Slide 10: Tumor Defence Breaker
THE SOLUTION TUMOR DEFENCE BREAKER™ Camelid nanobodies High binding affinity to L-DOS47 CEACAM6. Urease enzyme A first-in-class AEC that neutralizes the Catalyzes urea breakdown into ammonia and CO₂, neutralizing acidic pH of the TME, helping turn the pH of the TME. immunologically cold tumors “hot”
Slide 11: Mechanism of Action
MECHANISM OF ACTION T Cells A HALLMARK OF CANCER The TME is acidic. TME acidosis leads to: Immunotherapy L-DOS47 Immunosuppression (“cold” tumors) Resistance to treatment neutralizes tumor acidity, Cancer proliferation taking the brakes off anti-tumor Chemotherapy Metastasis immunity and delivering
Slide 12: A Force Multiplier for Anti-PD-1 Antibodies
A FORCE MULTIPLIER FOR ANTI-PD-1 ANTIBODIES Pembrolizumab + L-DOS47 synergistically and significantly reduces tumor growth, volume and weight compared to pembrolizumab alone in 28 days in pancreatic cancer mouse models. -70% greater tumor volume reduction -50% greater tumor weight reduction with L-D
Slide 13: Clinically Safe and Effective with Chemo
CLINICALLY SAFE AND EFFECTIVE WITH CHEMO L-DOS47 in combination with Pemetrexed/Carboplatin delivers 75% overall clinical benefit in a Phase IB, open-label dose-escalation study in heavily pre-treated patients with Stage IV NSCLC. EFFICACY & SAFETY — Best % Change in Lesion Size from Baseline (patie
Slide 14: Timely & Close to the Finish Line
TIMELY & CLOSE TO THE FINISH LINE L-DOS47 STRENGTHS L-DOS47 OPPORTUNITIES L-DOS47 NEXT STEPS 2026 2027 2028 2029 2030 2031 First-in-class TME AEC Significant improvement in PFS Phase Ib completed Significant improvement in OS CMC clinical batch Results highly encouraging ICI market share expansion “
Slide 15: CEACAM6: The Bigger Picture
THE BIGGER PICTURE CEACAM6 CEACAM6 (carcinoembryonic antigen-related cell Overexpressed in major cancers adhesion 6) is a cell-surface protein overexpressed CEACAM6 is significantly on hard-to-treat solid tumors and a highly low in healthy tissue. promising target for antibody-based therapies.1 Heli
Slide 16: Leveraging Radio-Ligand Technology in Discovery
PRODUCT 2, CEACAM6 PLATFORM CEACAM6 Product 2 LEVERAGING RADIO- CEACAM6-RL-PDAC (radio-ligand targeting CEACAM6-expressing pancreatic adenocarcinoma). LIGAND TECHNOLOGY IN DISCOVERY Design Radio-Isotope Single chain camelid nanobody Alpha emitter, carefully with CEACAM6 high binding selected to maxi
Slide 17: The Promise of Our Discovery ADCs
CEACAM6 Products 3 & 4 Conjugation PRODUCTS 3 & 4, CEACAM6 PLATFORM CEACAM6-GIT (Gastrointestinal) Newest linker system, THE PROMISE OF OUR CEACAM6-GYN (Gynecological) ensuring systemic stability. DISCOVERY ADCs Carefully-designed ADCs capitalising on latest, state-of-the- art technology. Design Pay
Slide 18: LEUMUNA
LEUMUNA™ An oral immune checkpoint modulator to bring long-term remission within reach for patients relapsing with leukemia. 17
Slide 19: Leukemia Relapse
THE PROBLEM LEUKEMIA RELAPSE More than 60,000 Allogeneic stem cell transplantation (allo-SCT) patients undergo allo-SCT each offers a potentially life-saving treatment for year.1 patients with hematological malignancies. But nothing is more devastating than seeing the Up to 30% or 18,000 Survival: ~
Slide 20: LEUMUNA
THE SOLUTION Activated T-Cells LEUMUNA™ A pre-IND, first-in-class oral immune checkpoint modulator and inhibitor of PNP to initiate graft- Activates transplanted versus-leukemia (GvL) effect in patients immune system to fight relapsing with leukemia after allogeneic SCT. resurging leukemia GvL is th
Slide 21: Evidence with LEUMUNA
EVIDENCE WITH LEUMUNA LEUMUNA significantly reduces risk of relapse mortality in preclinical minor-MHC mismatch B Cell Acute leukemia model. 1) Improvement in survival with LEUMUNA is due to T-cell OVERALL SURVIVAL 2) Risk of graft-versus-host disease (GVHD) mortality outweighed by COMPETING RISK AN
Slide 22: Historical Clinical Data
HISTORICAL CLINICAL DATA Predecessor compound, Ulodesine (BCX4208), developed in gout and psoriasis, and analog, forodesine hydrochloride. BCX4208: OUTSTANDING SAFETY AND TOLERABILITY COMPLETE REMISSION ACHIEVED A 3-year old pediatric patient was cured of relapsed T-Cell Acute Demonstrated in Phase
Slide 23: LEUMUNA Facts & Prospects
LEUMUNA FACTS & PROSPECTS LEUMUNA STRENGTHS LEUMUNA OPPORTUNITIES LEUMUNA NEXT STEPS 2026 2027 2028 2029 2030 FDA Orphan status Potential 2+ yrs. OS or cure CoM Patent (exp. 2041) Poised to become SoC CMC clinical batch Breakthrough potential and Supporting clinical evidence accelerated approval IND
Slide 24: GEMCEDA
GEMCEDA™ A first-in-class oral gemcitabine to enrich the spectrum of disease-limiting and life- enhancing outcomes for patients whose cancer has progressed. 23
Slide 25: Oral Gemcitabine
THE PROBLEM ORAL GEMCITABINE More than 30% Gemcitabine is a WHO-designated Essential of the 900 chemotherapy agents in development are oral agents, to Medicine used to treat one-third of all cancers improve access to care.2 and is among the most widely prescribed therapies worldwide.1 But with intra
Slide 26: GEMCEDA
GEMCEDA A pre-IND, first-in-class oral gemcitabine prodrug combined with cedazuridine, with bioavailability on par with IV (90%), for metronomic therapy to control tumor growth and preserve quality of life. 25
Slide 27: Gemcitabine Oral Chemotherapy
High-grade Serous High vs low replication stress (RB1, CDKN2A Ovarian Cancer* loss, or surplus of CCNE1, KRAS, MYC). Combination with PARP or ATR inhibitor. GEMCITABINE ORAL Pancreatic Ductal Use GemciTest ®️ to predict gemcitabine CHEMOTHERAPY Adenocarcinoma response. Target indications with biomar
Slide 28: GEMCEDA Facts & Prospects
GEMCEDA FACTS & PROSPECTS GEMCEDA STRENGTHS GEMCEDA OPPORTUNITIES GEMCEDA NEXT STEPS 2026 2027 2028 2029 2030 First-in-class oral gemcitabine IV gem. treats 1/3 of cancers Oral bioavailability ≈ IV Regulatory 505(b)2 pathway Tox & CMC clinical batch CoM Patent (exp. 2043) Maintenance therapy IND Est
Slide 29: The Bottom Line
THE BOTTOM LINE 28
Slide 30: Our Strategy
OUR STRATEGY Innovating from strength to shape a near future where hard-to-treat cancers are vincible. CANDIDATE L-DOS47 LEUMUNA™ GEMCEDA™ C6 RDCs & ADCs HARD-TO-TREAT Non-small cell lung Advanced solid Leukemia relapse Solid tumors CANCER cancer (NSCLC) tumors Synergistic efficacy with Backed by cl
Slide 31: Upcoming Milestones
Q2 2026 Q3 2026 Q4 2026 Q1 2027 Q2 2027 Q3 2027 UPCOMING Bridge financing (USD 25M) MILESTONES Relocation to US & NASDAQ listing FDA Meeting Our ambitious plan on our priority projects over the next 18 months. Public Offering (USD 80M) FPI (NSCLC in comb. with ICI) Financial / Corporate Milestone IN
Slide 32: Expert Collaborators' Opinions
EXPERT COLLABORATORS’ OPINIONS on Helix BioPharma’s most advanced assets. Professor Robert Gillies, Moffitt Cancer Center Vice-Chair Radiology, Director Professor Caius Radu, Departments of Molecular and Medical of Experimental Imaging Program & US Key Opinion Leader, on L-DOS47 Pharmacology and Sur
Slide 33: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation document contains certain forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable securities laws. Forward-looking statements are statements and information that are not historical facts but
Slide 34: Helix BioPharma
HELIX biopharma Shaping a near future where today’s hard-to-treat cancers are vincible. For investor relations, contact corporate@helixbiopharma.com HELIX BIOPHARMA CORP. 798 West Pender Street, Suite 480 Vancouver, British Columbia V6C 1H2 Tel: +1 857 208 7687 TSX: HBP Thomas Mehrling, CEO OTC PINK
Helix BioPharma — Investor Presentation (August 2026) on 6ix